Antisense oligonucleotides are used to study the expression and function of a diverse range of proteins. Areas for which antisense has been used for pharmacological investigation include receptors, neuropeptides and immediate early genes, particularly when specific ligands or markers are not yet available. Antisense oligonucleotides target a specific mRNA and block the expression of the protein by sequence specific hybridization. This technique has not only been shown to be a valuable pharmacological tool but also to have potential therapeutic applications. In this review we discuss the technology behind the technique including developments in methodology employed in antisense experiments. Although antisense provides a novel and highly specific tool, the reliability of the technique and many of the problems associated with antisense experiments are discussed. The main focus of this article is the use of antisense in psychopharmacology to investigate behavioural changes following antisense-mediated inhibition of the expression of specific brain proteins and receptors.
Agrawal S., Goodchild J., Civeira M.P., Thornton AT, Sarin PM, Zamecnik P.C. (1988) Oligodeoxynucleoside phosphoramidites and phosphorothioates as inhibitors of human immunodeficiency virus. Proc Nat Acad Sci USA85: 7079-7083
2.
Agrawal S., Temsamani J., Tang J.Y. (1991) Pharmacokinetics, biodistribution and stability of oligodeoxynucleotide phosphorothioates in mice. Proc Nat Acad Sci USA88: 7595-7599
3.
Akabayashi A., Wahlestedt C., Alexander J.T., Leibowitz S.F. (1994) Specific inhibition of endogenous neuropeptide Y synthesis in arcuate nucleus by antisense oligonucleotides suppresses feeding behaviour and insulin secretion. Mol Brain Res21: 55-61
4.
Anazodo M.I., Wainberg M.A., Friesen A.D., Wright JA (1995) Inhibition of human immunodeficiency virus type 1 (HIV) gag gene expression by an antisense oligodeoxynucleotide phosphorothioate . Leukaemia9 (Suppl. 1): S86-S88
Bourson A., Borroni E., Austin R.H., Monsma J.Jr, Sleight A.J. (1995) Determination of the role of the 5-ht 6 receptor in the rat brain: a study using antisense oligonucleotides. J Pharmac Exp Ther274: 173-180
7.
Brysch W., Schlingensiepen K-H. (1994) Design and application of antisense oligonucleotides in cell culture, in vivo and as therapeutic agents. Cell Mol Neurobiol14: 555-567
8.
Campbell JM, Bacon TA, Wickstrom E. (1990) Oligodeoxynucleoside phosphorothioate stability in subcellular extracts, culture media, sera and cerebrospinal fluid. J Biochem Biophys Meth20: 259-267
9.
Chapman A.G., Woodburn V.L., Woodruff G.N., Meldrum B.S. (1995) Inhibition of sound-induced seizures and c-fos expression in DBA/2 mice by an antisense probe to NMDA-R1 receptor subunit. Br J Pharmac114: 324P
10.
Chen X-H.,Adams J.U., Geller E.B., DeRiel J.K., Adler M.A., Liu-Chen L-Y. (1995) An antisense oligodeoxynucleotide to μ-opioid receptors inhibit μ-opioid receptor agonist-induced analgesia in rats . Eur J Pharmac275: 105-108
11.
Chiasson B.J., Hooper M.L., Murphy P.R., Robertson H.A. (1992) Antisense oligonucleotide eliminates in vivo expression of c-fos in mammalian brain. Eur J Pharmac—Mol Pharmac Sec227: 451-453
12.
Chiasson B.J., Armstrong J.N., Hooper M.L., Murphy P.R., Robertson H.A. (1994) The application of antisense oligonucleotide technology to the brain: some pitfalls. Cell Mol Neurobiol14:507-521
13.
Chiang M.Y., Chan H., Zounes M.A., Freier S.M., Lima W.F., Bennett C.F. (1991) Antisense oligonucleotides inhibit intercellular adhesion molecule 1 expression by two distinct mechanisms. J Biol Chem266: 162-171
14.
Chien C.C., Brown G., Pan X-Y., Pasternak G.W. (1994) Blockade of U50, 488H analgesia by antisense oligodeoxynucleotides to a κ-opioid receptor. Eur J Pharmac253: R7-8
15.
Cooke S.T. (1992) Therapeutic applications of oligonucleotides. Ann Rev Pharmac Toxicol32: 329-376
16.
Davis M. (1992) The role of the amygdala in fear and anxiety. Ann Rev Neurosci15: 353-375
17.
Di Scala-Guenot D., Strosser MT, Freund-Mercier MJ, Richard P. (1990) Characterisation of oxytocin-binding sites in primary rat brain cell cultures. Brain Res524:10-16
18.
Dragunow M., Lawlor P., Chaisson B., Robertson H. (1993) C-fos antisense generates apomorphine and amphetamine-induced rotation. Neuroreport5: 305-306
19.
Dunn AJ, Berridge CW (1990) Physiological and behavioural response to corticotropin-releasing factor administration: Is CRF a mediator of anxiety or stress response?Brain Res Rev15: 71-100
20.
Eckstein F. (1983) Phosphorothioate analogues of nucleotides— tools for the investigation of biochemical processes. Ang Chem22:423-506
21.
Evans C.J., Keith D.E. Jr, Morrison H., Magendzo K., Edwards R.H. (1992) Cloning of a delta opioid receptor by functional expression. Science258: 1952-1955
22.
Fukuda K., Katto S., Mori K., Nishi M., Takeshima H. (1993) Primary structures and expression from cDNAs of rat opioid receptors from δ and μ -subtypes. FEBS Letts327: 311-314
23.
Graybiel AM, Moratalla R., Robertson H.A. (1990) Amphetamine and cocaine induce drug-specific activation of the c-fos gene in striosome-matrix compartments and limbic subdivisions of the striatum. Proc Nat Acad Sci USA87: 6912-6916
Heilig M., Engel J.A., Söderpalm B. (1993) C-fos antisense in the nucleus accumbens blocks the locomotor stimulant action of cocaine. Eur J Pharmac236: 339-340
26.
Heilig M. (1994) Antisense technology. Prospects for treatment of neuropsychiatric disorders. CNS Drugs1: 405-409
27.
Helene C. (1994) Control of oncogene expression by antisense nucleic acids. Eur J Cancer11: 1721-1726
28.
Holsboer F., Spengler D., Heuser I. (1992) The role of corticotropin-releasing hormone in the pathogenesis of Cushing's disease, anorexia nervosa, alcoholism, affective disorder and dementia. Prog Brain Res93: 385-417
29.
Hooper M.L., Chaisson B.J., Robertson H.A. (1994) Infusion into the brain of an antisense oligonucleotide to the immediate-early gene c-fos suppresses production of fos and produces a behavioural effect. Neuroscience63: 917-924
30.
Hoyer D., Clarke D.E., Fozard J.R., Hartig P.R., Martin G.R., Mylecharane E.J., Saxena P.R., Humphrey P PA (1994) VII International Union of Pharmacology classification of receptor for 5-hydroxytryptamine (serotonin). Pharmac Rev46: 157-203
31.
Johnson R.S., Spiegelman B.M., Papaioannou V. (1992) Pleiotropic effects of a null mutation in the c-fos proto-oncogene. Cell71: 577-586
32.
Juliano R.L., Akhtar S. (1992) Liposomes as a drug delivery system for antisense oligonucleotides. Antisense Res Dev2:165-176
33.
Karle J., Witt M.R., Neilsen M. (1995) Antisense oligonucleotides to GABA A gamma 2 subunit induces loss of neurones in rat hippocampus. Neurosci Letts202:97-100
34.
Kean J.M., Kipp SA, Miller P.S., Kulka M., Aurelian L. (1995) Inhibition of herpes simplex virus replication by antisense oligo-2'-O-methylribonucleoside methylphosphonates. Biochemistry34: 14617-14620
35.
Kieffer B.L., Befort K., Gaveriaux-Ruff C., Hirth C.G. (1992) The δ-opioid receptor: isolation of a cDNA by expression cloning and pharmacological characterisation. Proc Nat Acad Sci USA89: 12048-12052
36.
Kirkland M.A., O'Brian S.G., McDonald C., Davidson R.J., Cross N C R, Goldman J.M. (1993) BCR-ABL antisense purging in chronic myeloid leukaemia (3). Lancet342: 614
37.
Kitajama I., Shinohara T., Bilakovics J., Brown D.A., Xu X., Nerenberg M. (1993) Ablation of transplanted HTLV-I tax-transformed tumors in mice by antisense inhibition of NF-Kappa B. Science258: 1792-1795
38.
Koob G.F. (1992) Dopamine addiction and reward. Semin Neurosci4:139-148
39.
Korba B.E., Gerin J.L. (1995) Antisense oligonucleotides are effective inhibitors of hepatitis B replication in vitro. Antiviral Res28: 225-242
40.
Koschel K., Brinckmann U., Hoyningen-Huene V.V. (1995) Measles virus antisense sequences specifically cure cells persistently infected with measles virus. Virology207:168-178
41.
Krieg A.M. (1993) Uptake and efficacy of phosphodiester and modified antisense oligonucleotides in primary cell cultures. Clin Chem39: 710-712
42.
Krieg A.M., Tonkinson J., Matson S., Zhao Q., Saxon M., Zhang L-M., Bhanja U., Yakubov L., Stein CA (1993) Modification of a phosphodiester oligodeoxyribonucleotide by a 5'-cholesteryl moiety increases cellular association and improves efficacy . Proc Nat Acad Sci USA90:1048-1052
43.
Lai J., Bilsky E.J., Porreca F. (1995) Treatment with antisense oligodeoxynucleotide to a conserved sequence of opioid receptors inhibits antinociceptive effects of delta subtype selective ligands. J Recept Sig Transd Res15: 643-650
44.
Landgraf R., Gerstberger R., Montkowski A., Probst J.C., Wotjak C.T., Holsboer F., Engelmann M. (1995) V1 vasopressin receptor antisense oligodeoxynucleotide into septum reduces vasopressin binding, social discrimination abilities, and anxiety-related behaviour in rats. J Neurosci15: 4250-4258
45.
LeDoux J.E. (1992) Brain mechanisms of emotion and emotional learning . Curr Opin Neurobiol2:191-197
Mani S.K., Blaustein J.D., Allen J M C, Law S.W., O'Malley B.W., Clark J.H. (1994a) Inhibition of rat sexual behaviour by antisense oligonucleotides in the progesterone receptor. Endocrinology135: 1409-1414
48.
Mani S.K., Allen J M C, Clark J.H., Blaustein J.D., O'Malley B.W. (1994b) Convergent pathways for steroid hormone and neurotransmitter-induced rat sexual behaviour. Science265: 1246-1249
49.
Meeker R., LeGrand G., Ramirez J., Smith T., Shih Y-H. (1995) Antisense vasopressin oligonucleotides: Uptake, turnover, distribution, toxicity and behavioural effects. J Neuroendocrinol7:419-428
50.
Meldrum B.S. (1992) Excitatory amino acids in epilepsy and potential novel therapies. Epilepsy Res12: 189-196
51.
Meldrum B., Garthwaite J. (1990) Excitatory amino acid neurotoxicity and neurodegenerative disease. Trends Pharmac Sci11: 379-387
52.
Meng F., Xie G-X.,Thompson R.C., Mansour A., Goldstein A., Watson S.J., Akil H. ( 1993) Cloning and pharmacological characterisation of a rat kappa-opioid receptor. Proc Nat Acad Sci USA90: 9954-9958
53.
Miller P.S., McFarland K.B., Jayaraman K., Ts'o Pop (1981) Biochemical and biological effects of non-ionic nucleic acid methylphosphonates. Biochemistry20:1874-1880
54.
Möller C., Bing O., Heilig M. (1994) C-fos expression in the amygdala: in vivo antisense modulation and role in anxiety. Cell Mol Neurobiol14: 415-423
55.
Narita M., Tseng L.F. (1995) Stimulation of spinal δ-opioid receptors in mice selectively enhances the attenuation of δ-opioid receptor-mediated antinociception by antisense oligodeoxynucleotide. Eur J Pharmac284:185-189
56.
Nissbrandt H., Ekman A., Eriksson E., Heilig M. (1995) DA D3 receptor antisense influences dopamine synthesis in rat brain. Neuroreport6: 573-576
57.
Nunes J.P. (1995) Central α2-adrenoceptors and blood pressure regulation in the rat. Eur J Pharmac278: 183-185
58.
Ogawa S., Brown H.E., Okano H.J., Pfaff D.N. (1995) Cellular uptake of intracerebrally administered oligodeoxynucleotides in mouse brain. Reg Pep59:143-149
59.
Owens M.J., Bissette G., Nemeroff C.B. (1989) Acute effects of alprazolam and adinazolam on the concentrations of corticotropin-releasing factor in the rat brain. Synapse4:196-202
60.
Owens M.J., Nemeroff C.B. (1991) The physiology and pharmacology of corticotropin-releasing factor. Pharmac Rev43: 425-473
61.
Pan Y-X., Cheng J., Xu J., Rossi G., Jacobson E., Ryan-Moro J., Brooks AI, Dean GE, Standifer KM, Pasternak GW (1995) Cloning and functional characterization through antisense mapping of a κ3related opioid receptor. Mol Pharmac47:1180-1188
62.
Pasternak G.W., Standifer K.M. (1995) Mapping of opioid receptors using antisense oligodeoxynucleotides: correlating their molecular biology and pharmacology. Trends Pharmac Sci16: 344-350
63.
Richardson N.R., Piercy M.F., Svensson K., Collins R.J., Myers J.E., Roberts D.C. (1993) Antagonism of cocaine self-administration by preferential dopamine autoreceptor antagonist, (+)-AJ 76. Brain Res619:15-23
64.
Roth B.L., Craigo S.C., Choudhary M.S., Uluer A., Monsma FJ, ShenY., Meltzer H.Y., Sibley D.R. (1994) Binding of typical and atypical antipsychotic agents of 5-hydroxytryptamine-6 and 5-hydroxytryptamine-7 receptors. J Pharmac Exp Ther268: 1403-1410
65.
Ruat M., Traiffort E., Arrang J.M., Tardivel-Lacombe J., Diaz J., Leurs R., Schwartz J.C. (1993) A novel rat serotonin (5-ht6) receptor: molecular cloning, localisation and stimulation of cAMP accumulation. Biochem Biophys Res Commun193: 269-276
66.
Seeman P., Lee T., Chau-Wang M., Wang K. ( 1976) Antipsychotic drug doses and neuroleptic/dopamine receptors . Nature261: 717-719
67.
Seeman P. (1980) Brain DA receptors. Pharmac Rev32: 229-313
68.
Silvia C.P., King G.R., Lee T.H., Xue Z-Y., Caron M.G., Ellinwood E.H. (1994) Intranigral administration of D2 dopamine receptor antisense oligodeoxynucleotides establishes a role for nigrostriatal D2 autoreceptors in the motor actions of cocaine. Mol Pharmac46: 51-57
69.
Simons M., Edelman E.R., DeKeyser J-L., Langer R., Rosenberg R.D. (1992) Antisense c-myb oligonucleotides inhibit intimal arterial smooth muscle cell accumulation in vivo. Nature359: 67-70
70.
SkutellaT., Montkowski A., Stöhr T., Probst J.C., Landgraf R., Holsboer F., Jirikowski G.F. (1994a) Corticotrophin-releasing hormone (CRH) antisense oligodeoxynucleotide treatment attenuates social defeat-induced anxiety in rats. Cell Mol Neurobiol14: 579-588
71.
SkutellaT., Probst J.C., Jirikowski G.F., Holsboer F., Spangel R. (1994b) Ventral tegmental area (VTA) injections of tyrosine hydroxylase phosphorothioate antisense oligonucleotide suppress operant behaviour in rats. Neurosci Letts167: 55-58
72.
Sleight AJ, Carolo C., Petit N., Zwingelstein C., Bourson A. (1995) Identification of 5-hydroxytryptamine 7 receptor binding sites in rat hypothalamus: sensitivity to chronic antidepressant treatment. J Pharmac Exp Ther47: 99-103
73.
Smith D.W., Parker E.M. (1995) G protein-coupled serotonin receptors—multiple subtypes, multiple opportunities. Curr Pharmaceut Des:1:363-372
74.
Sokoloff P., Giros B., Martres M.P., Bouthenet M.L., Schwartz J.C. (1990) Molecular cloning and characterisation of a novel DA receptor D3) as a target for neuroleptics. ( Nature347: 146-151
75.
Sommer W., Bjelke B., Ganten D., Fuxe K. ( 1993) Antisense oligonucleotide to c-fos induces ipsilateral rotational behaviour to d-amphetamine. Neuroreport5: 277-280
76.
Standifer K.M., Chien C-C., Wahlestedt C., Brown G.P., Pasternak G.W. (1994) Selective loss of δ opioid analgesia and binding by a δ opioid receptor. Neuron12: 805-810
77.
Stein C.A. (1992) Antisense oligonucleotides—promises and pitfalls . Leukemia6: 967-974
78.
Stein CA, Cheng Y-C. (1993) Antisense oligonucleotides as therapeutic agents—Is the bullet really magical?Science261: 1004-1012
79.
Stephenson M.L., Zamecnik P.C. (1978) Inhibition of rous sarcoma virus replication and cell transformation by a specific oligodeoxynucleotide. Proc Nat Acad Sci USA75: 285-288
80.
Strauss M., Hering S., Lieber A., Herrmann G., Griffin B.E., Arnold W. (1992) Stimulation of cell division and fibroblast focus formation by antisense repression of retinaoblastoma protein synthesis. Oncogene7: 769-773
81.
Sun F-S., Faden A.I. (1995) Pretreatment with antisense oligodeoxynucleotides directed against the NMDA-R1 receptor enhances survival and behavioural recovery following traumatic brain injury in rats. Brain Res693: 163-168
82.
Takizawa S., Hogan M., Hakim AM (1991) The effect of a competitive NMDA receptor antagonist (CGS-19755) on cerebral blood flow and pH in focal ischaemia. J Cereb Blood Flow Metab11: 786-793
83.
Thomas E. (1988) Forebrain mechanisms in the relief of fear: The role of the lateral septum. Psychobiology16: 36-44
84.
Toulme JJ (1992) Artificial regulation of gene expression by complementary oligonucleotides-an overview. In Antisense RNA and DNA. Wiley-Liss, New York, pp.175-194
85.
Vogel J.R., Beer R., Clodt D.E. (1971) A simple and reliable conflict procedure for testing anti-anxiety agents. Psychopharmacologia21: 1-7
86.
Wachtel S.R., Brooderson R.J., White FJ (1992) Parametric and pharmacological analysis of the enhanced grooming response elicited by the D1 dopamine receptor agonist SKF38393 in the rat. Psychopharmacology109: 41-48
Wahlestedt C., Golanov E., Yamamoto S., Yee F., Ericson H., Yoo H., Inturrisi C.E., Reis D.J. (1993a) Antisense oligodeoxynucleotides to NMDA-R1 receptor channel protect cortical neurones from excitotoxicity and reduce focal ischaemic infarctions. Nature363: 260-263
90.
Wahlestedt C., Merlo-Pich E., Koob G.F., Yee F., Heilig M. (1993b) Modulation of anxiety and neuropeptide Y-Y1 receptors by antisense oligodeoxynucleotides. Science259: 528-531
91.
Wahlestedt C. (1994) Antisense oligonucleotide strategies in neuropharmacology . Trends Pharmac Sci15: 42-46
92.
Walder R.Y., Walder J.A. (1988) Role of RNaseH in hybrid-arrested translation by antisense oligonucleotides. Proc Nat Acad Sci85: 5011-5015
93.
Wang Z.Q., Ovitt C., Grigoriadis A.E., Mohle-Steinlein U., Ruther U., Wagner E.F. (1992) Bone and haematopoietic defects in mice lacking c-fos. Nature360: 741-745
Whitesell L., Geselowitz D., Chavany C., Fahmy B., Walbridge S., Alger J.R., Neckers L.M. (1993) Stability, clearance and deposition of intraventricularly administered oligodeoxynucleotides: implications for therapeutic application within the central nervous system. Proc Nat Acad Sci USA90: 4665-4669
96.
Wickstrom E. (1986) Oligonucleotide stability in subcellular extracts and culture media. J Biochem Biophys Meth13: 97-102
97.
Woolf T.M., Melton D.A., Jennings C G B (1992) Specificity of antisense oligonucleotides in vivo . Proc Nat Acad Sci USA89: 7305-7309
98.
Zhang M., Creese I. (1993) Antisense oligodeoxynucleotide reduces brain dopamine D2 receptors: behaviour correlates. Neurosci Letts161: 223-226
99.
Zhang S., Zhou L., Weiss B. (1994) Oligodeoxynucleotide antisense to the D 1 dopamine receptor mRNA inhibits D1 dopamine receptor-mediated behaviours in normal mice and in mice lesioned with 6-hydroxydopamine. J Pharmac Exp Ther271: 1462-1470
100.
Zhang M., Quagazzal A., Creese I. (1995) Differential roles for dopamine D 2 receptor subtypes in locomotor activity and stereotypy: Antisense knockout studies. Soc Neurosci Abstr21: 364
101.
Zhou L-W., Zhang S-P., Connell T.A., Weiss B. (1993a) Cholinergic lesions of mouse striatum induced byAF64A alter dopaminergic behaviour and reduce D2 dopamine receptors and D2 dopamine receptor mRNA. Neurochem Int22: 301-311
102.
Zhou L-W., Zhang S-P., Connell T.A., Weiss B. (1993b) AF64A lesions of mouse striatum results in ipsilateral rotations to D2 dopamine agonists but contralateral rotations to muscarinic cholinergic agonists. J Pharmac Exp Ther264: 824-830
103.
Zhou L-W., Zhang S-P., Qin Z-H., Weiss B. (1994) In vivo administration of an oligodeoxynucleotide antisense to the D2 dopamine receptor messenger RNA inhibits D2 dopamine receptor-mediated behaviour and the expression of D 2 dopamine receptors in mouse striatum. J Pharmac Exp Ther268:1015-1023
